A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease

Inclusion Criteria: * Understood and signed an informed consent form. * ≥18 years old, Karnofsky Performance Scale of ≥60, life expectancy ≥ 6 months. * Has received allogeneic hematopoietic stem cell transplantation (alloSCT). * Clinically diagnosed moderate to severe cGVHD according to NIH Consensus Criteria. * Has received systemic or topical corticosteroids therapy and confirmed steroid-refractory/dependent cGVHD according to NIH Consensus Criteria. * Has received at least 1 lines of therapy for cGVHD. * Adequate laboratory indicators. * No pregnant or breastfeeding women, and a negative pregnancy test. Exclusion Criteria: * Has active acute GVHD. * Has previously failed to respond to JAK inhibitors for GVHD, or who had used JAK inhibitors within 4 weeks before the first administration. * Has uncontrollable active infections or infections requiring systematic treatment within 7 days before the first administration. * Development of other basic diseases. * Has malignant tumors within 3 years. * Has multiple factors affecting oral medication. * Has substance abuse or a psychotic disorder. * Has severe and / or uncontrolled disease. * Allergic to drugs or its constituents. * Has participated in any other clinical trials within 4 weeks before first administration. * According to the judgement of the investigators, there are other factors that may lead to the termination of the study.